Gaussian Boson Samplers are photonic quantum devices with the potential to perform intractable tasks for classical systems. As with other near-term quantum technologies, an outstanding challenge is to identify specific problems of practical interest where these devices can prove useful. Here, we show that Gaussian Boson Samplers can be used to predict molecular docking configurations, a central problem for pharmaceutical drug design. We develop an approach where the problem is reduced to finding the maximum weighted clique in a graph, and show that Gaussian Boson Samplers can be programmed to sample large-weight cliques, i.e., stable docking configurations, with high probability, even with photon losses. We also describe how outputs from the device can be used to enhance the performance of classical algorithms. To benchmark our approach, we predict the binding mode of a ligand to the tumor necrosis factor-αconverting enzyme, a target linked to immune system diseases and cancer.
Molecular docking with Gaussian Boson Sampling / Banchi L.; Fingerhuth M.; Babej T.; Ing C.; Arrazola J.M.. - In: SCIENCE ADVANCES. - ISSN 2375-2548. - ELETTRONICO. - 6:(2020), pp. 0-0. [10.1126/sciadv.aax1950]
Molecular docking with Gaussian Boson Sampling
Banchi L.
;
2020
Abstract
Gaussian Boson Samplers are photonic quantum devices with the potential to perform intractable tasks for classical systems. As with other near-term quantum technologies, an outstanding challenge is to identify specific problems of practical interest where these devices can prove useful. Here, we show that Gaussian Boson Samplers can be used to predict molecular docking configurations, a central problem for pharmaceutical drug design. We develop an approach where the problem is reduced to finding the maximum weighted clique in a graph, and show that Gaussian Boson Samplers can be programmed to sample large-weight cliques, i.e., stable docking configurations, with high probability, even with photon losses. We also describe how outputs from the device can be used to enhance the performance of classical algorithms. To benchmark our approach, we predict the binding mode of a ligand to the tumor necrosis factor-αconverting enzyme, a target linked to immune system diseases and cancer.File | Dimensione | Formato | |
---|---|---|---|
sciadv.aax1950-1.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
594.45 kB
Formato
Adobe PDF
|
594.45 kB | Adobe PDF | |
sciadv.aax1950(1).pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
594.41 kB
Formato
Adobe PDF
|
594.41 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.